LYON, FRANCE--(Marketwired - May 9, 2016) - Flamel Technologies (NASDAQ: FLML) today announced its financial results for the first quarter of 2016.
First Quarter Highlights Include:
Total revenue for first quarter 2016 was $36.2 million, compared to $32.7 million during the same period last year.
GAAP net loss for the first quarter was ($6.4) million, or ($0.15) per diluted share, compared to GAAP net income of $11.6 million, or $0.27 per diluted share during the same period last year.
Adjusted EBITDA was $11.8 million, compared to $12.9 million in the prior year.*
Adjusted net income for the first quarter was $1.6 million, or $0.04 per diluted share, compared to an adjusted net income of $4.7 million, or $0.11 per diluted share, during the same period last year. *
Cash and marketable securities at March 31, 2016 were $160.0 million, compared to $144.8 million at December 31, 2015 and $113.2 million at March 31, 2015.
Special Protocol Assessment (SPA) submitted to the U.S. Food and Drug Administration (FDA) for the once nightly version of Micropump® sodium oxybate.
First Quarter Highlights Include:
Total revenue for first quarter 2016 was $36.2 million, compared to $32.7 million during the same period last year.
GAAP net loss for the first quarter was ($6.4) million, or ($0.15) per diluted share, compared to GAAP net income of $11.6 million, or $0.27 per diluted share during the same period last year.
Adjusted EBITDA was $11.8 million, compared to $12.9 million in the prior year.*
Adjusted net income for the first quarter was $1.6 million, or $0.04 per diluted share, compared to an adjusted net income of $4.7 million, or $0.11 per diluted share, during the same period last year. *
Cash and marketable securities at March 31, 2016 were $160.0 million, compared to $144.8 million at December 31, 2015 and $113.2 million at March 31, 2015.
Special Protocol Assessment (SPA) submitted to the U.S. Food and Drug Administration (FDA) for the once nightly version of Micropump® sodium oxybate.
